• Wondering whether Harrow at US$40.50 still offers value, or if most of the opportunity is already priced in? This article is built to help you frame that question clearly.
• The stock has returned 14.7% over the past 30 days, sits on a 67.9% return over 1 year, but is still down 18.9% year to date. This raises fair questions about both upside potential and risk.
• Recent coverage has focused on Harrow's position in the pharmaceuticals space and how investors are reacting to its latest developments, with attention on whether the current share price fairly reflects the business outlook. This backdrop helps explain why the stock has seen periods of strong performance alongside bouts of caution.
• Harrow currently holds a valuation score of 3 out of 6. Next you will see how different valuation methods frame that score, followed by a broader way to think about what the stock might really be worth.

Approach 1: Harrow Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows and discounts them back to today, aiming to estimate what those cash flows are worth in current dollars.

For Harrow, the latest twelve months free cash flow (FCF) is a loss of $43.12 million. Analysts and model estimates project FCF turning positive in coming years, with specific figures provided out to 2035. For example, projected FCF for 2030 is $409.20 million, with intermediate years such as 2026 and 2027 modeled at $59.40 million and $117.50 million respectively. Beyond the initial analyst estimates, Simply Wall St extrapolates further projections to complete the 2 Stage Free Cash Flow to Equity model.

When all those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $329.35 per share. Compared with the current price of US$40.50, this implies the stock is 87.7% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Harrow is undervalued by 87.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Harrow Price vs Sales

For profitable and revenue generating companies, the P/S ratio is a useful way to compare what investors are paying for each dollar of sales, especially when earnings are volatile or not yet a steady guide.

Growth expectations and risk matter here because a higher expected growth rate or lower perceived risk can justify a higher P/S multiple, while slower growth or higher risk usually calls for a lower and more conservative multiple.

Harrow currently trades on a P/S ratio of 5.54x. This sits close to the Pharmaceuticals industry average of 5.47x and above the peer group average of 4.60x. Simply Wall St adds another layer with its proprietary Fair Ratio, which estimates what P/S multiple might be reasonable for Harrow based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. For Harrow, this Fair Ratio is 7.30x.

Because the Fair Ratio is tailored to Harrow rather than being a simple peer or industry comparison, it can provide a more company specific view. With the Fair Ratio above the current 5.54x P/S, this multiple based lens suggests that the stock may be undervalued on a sales basis.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose Your Harrow Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, providing a simple way for you to attach a clear story about Harrow to the numbers you are using for fair value, future revenue, earnings and margins.

A Narrative on Simply Wall St connects three pieces in one place on the Community page that is used by millions of investors: your view of the business story, a financial forecast that reflects that view, and a resulting fair value.

This helps you decide what to do by comparing your Narrative Fair Value to Harrow’s current share price and seeing whether the gap between them is wide enough, or has closed enough, to justify taking action or waiting.

Because Narratives update automatically when new earnings, guidance or news are added to the platform, you are not limited to a static model that quickly goes out of date.

For Harrow, one investor might align with the more cautious Narrative that ties to a fair value of US$59.00, while another might prefer the more optimistic Narrative closer to US$89.62. Both can see exactly which revenue, margin and P/E assumptions sit behind those very different views.

Do you think there's more to the story for Harrow? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.